Disc Medicine Inc. (IRON) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Disc Medicine Inc. (IRON) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How IRON Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -5.9% | -$212.2M | -$181.3M | -27.5% |
| FY 2024 | $4.00B | 0% | -3.2% | -$109.4M | -$94.4M | -37.3% |
| FY 2023 | $4.00B | 0% | -2.3% | -$76.4M | -$73.5M | -5.9% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring IRON)
- ✓Live walkthrough of IRON's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
IRON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IRON today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IRON. Explore sector supply chains on /butterfly.
IRON Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Disc Medicine Inc. (IRON)?
In FY 2025 (10-K), IRON converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).